Bladder Cancer Journal

Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment ABSTRACT: BACKGROUND:...

Upregulated FGFR3 signaling in NMIBC and MIBC, the diagnosis and management of checkpoint inhibitor side effects in bladder cancer patients, the etiology of treatment delays in patients receiving neoadjuvant chemotherapy for MIBC, and 25-year trends in stage-specific incidence rates for bladder cancer.

Bladder Cancer Journal Vol. 6 Issue 3 The Urinary Microbiome and Bladder Cancer: Susceptibility...

Bladder Cancer Journal Vol. 6 Issue 2 Considerations about Non-Metastatic Bladder Cancer...

Bladder Cancer Journal Vol. 6 Issue 1 Chemotherapy Plus Immune Check-Point Inhibitors in...